JPWO2023077013A5 - - Google Patents
Info
- Publication number
- JPWO2023077013A5 JPWO2023077013A5 JP2024525333A JP2024525333A JPWO2023077013A5 JP WO2023077013 A5 JPWO2023077013 A5 JP WO2023077013A5 JP 2024525333 A JP2024525333 A JP 2024525333A JP 2024525333 A JP2024525333 A JP 2024525333A JP WO2023077013 A5 JPWO2023077013 A5 JP WO2023077013A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- aav
- rna
- engineered
- disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163272418P | 2021-10-27 | 2021-10-27 | |
| US63/272,418 | 2021-10-27 | ||
| US202163277662P | 2021-11-10 | 2021-11-10 | |
| US63/277,662 | 2021-11-10 | ||
| US202263333256P | 2022-04-21 | 2022-04-21 | |
| US63/333,256 | 2022-04-21 | ||
| PCT/US2022/078801 WO2023077013A1 (en) | 2021-10-27 | 2022-10-27 | Engineered rnas |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024543000A JP2024543000A (ja) | 2024-11-19 |
| JPWO2023077013A5 true JPWO2023077013A5 (https=) | 2025-11-04 |
| JP2024543000A5 JP2024543000A5 (https=) | 2025-11-04 |
Family
ID=84363850
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024525333A Pending JP2024543000A (ja) | 2021-10-27 | 2022-10-27 | 操作されたｒｎａ |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20250084408A1 (https=) |
| EP (1) | EP4423266A1 (https=) |
| JP (1) | JP2024543000A (https=) |
| AU (1) | AU2022375788A1 (https=) |
| CA (1) | CA3236122A1 (https=) |
| WO (1) | WO2023077013A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2026504808A (ja) * | 2023-01-18 | 2026-02-10 | アプター バイオ，インク． | 神経変性疾患の処置のためのポリヌクレオチド組成物および方法 |
| EP4652278A1 (en) * | 2023-01-18 | 2025-11-26 | Aptah Bio, Inc. | Polynucleotide compositions and methods for treatment of cancer |
| EP4713450A1 (en) * | 2023-05-15 | 2026-03-25 | Shape Therapeutics Inc. | Engineered constructs with cassette arrangements for increased transcription of rna payloads |
| WO2025019685A2 (en) * | 2023-07-18 | 2025-01-23 | Allen Institute | Antisense oligonucleotides and artificial expression constructs for expressing rna in inhibitory neurons |
| WO2025085607A1 (en) * | 2023-10-20 | 2025-04-24 | The Children's Medical Center Corporation | Compositions and methods for prevention and treatment of genetic disease |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9040491B2 (en) * | 2006-08-30 | 2015-05-26 | The Trustees Of The University Of Pennsylvania | Compositions, methods and kits based on small nuclear RNAs |
| WO2015190921A2 (en) * | 2014-06-10 | 2015-12-17 | Erasmus University Medical Center Rotterdam | Methods for characterizing alternatively or aberrantly spliced mrna isoforms |
| US10676737B2 (en) * | 2014-12-17 | 2020-06-09 | Proqr Therapeutics Ii B.V. | Targeted RNA editing |
| WO2020001793A1 (en) * | 2018-06-29 | 2020-01-02 | Eberhard-Karls-Universität Tübingen | Artificial nucleic acids for rna editing |
| EP4008784A1 (en) * | 2019-08-01 | 2022-06-08 | Astellas Pharma Inc. | Guide rna for targeted-editing with functional base sequence added thereto |
| WO2021113270A1 (en) * | 2019-12-02 | 2021-06-10 | Shape Therapeutics Inc. | Therapeutic editing |
| MX2022006991A (es) * | 2019-12-09 | 2022-08-25 | Astellas Pharma Inc | Arn guía antisentido con región funcional añadida para editar arn blanco. |
| CN115777020A (zh) * | 2020-04-22 | 2023-03-10 | 塑造治疗公司 | 使用snrna组分的组合物和方法 |
-
2022
- 2022-10-27 US US18/704,897 patent/US20250084408A1/en active Pending
- 2022-10-27 AU AU2022375788A patent/AU2022375788A1/en active Pending
- 2022-10-27 EP EP22813847.5A patent/EP4423266A1/en active Pending
- 2022-10-27 WO PCT/US2022/078801 patent/WO2023077013A1/en not_active Ceased
- 2022-10-27 CA CA3236122A patent/CA3236122A1/en active Pending
- 2022-10-27 JP JP2024525333A patent/JP2024543000A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPWO2021216853A5 (https=) | ||
| US20230203483A1 (en) | Compositions and Methods Using SNRNA Components | |
| US12234449B2 (en) | CRISPR/Cas-related methods and compositions for treating Leber's congenital amaurosis 10 (LCA10) | |
| US20230242910A1 (en) | Methods and compositions relating to engineered guide systems for adenosine deaminase acting on rna editing | |
| US20210380987A1 (en) | Crispr/cas-related methods and compositions for treating cystic fibrosis | |
| GB2590880A (en) | RNA and DNA base editing via engineered ADAR recruitment | |
| US20240084334A1 (en) | Serpina-modulating compositions and methods | |
| JPWO2020247882A5 (https=) | ||
| JP6872479B2 (ja) | 筋萎縮性側索硬化症の処置 | |
| CN107406852B (zh) | 用于莱伯氏先天性黑蒙的寡核苷酸疗法 | |
| AU2015367378A1 (en) | Targeted RNA editing | |
| JP2024543000A (ja) | 操作されたｒｎａ | |
| JP2024099770A5 (https=) | ||
| JPWO2023077013A5 (https=) | ||
| US20240398990A1 (en) | Liver-specific expression cassettes, vectors and uses thereof for expressing therapeutic proteins | |
| JPWO2020082047A5 (https=) | ||
| CN120129747A (zh) | snRNA核酸分子及其应用 | |
| CA3236391A1 (en) | Rna-editing compositions and methods of use | |
| US20250027115A1 (en) | Conjugates of guide RNA-Cas protein complex for genome and epigenome editing | |
| JPWO2023015297A5 (https=) | ||
| JPWO2021076941A5 (https=) | ||
| TW202405173A (zh) | 用於增強aav療法及降低aav向肝臟之趨性的組合物及方法 | |
| CA3257367A1 (en) | ENHANCED OLIGONUCLEOTIDES TARGETTING RNA-BINDING PROTEIN SITES | |
| JPWO2020160121A5 (https=) | ||
| CN118871582A (zh) | 靶向lrrk2的rna编辑工程化指导rna和多核苷酸 |